Loss of AMPKα2 promotes melanoma tumor growth and brain metastasis

Area of Science:

• Molecular Biology
• Cancer Research
• Metabolism

Background:

• AMP-activated protein kinase (AMPK) is a key cellular energy sensor.
• Its precise role in cancer, particularly melanoma, is not fully understood.
• The PRKAA2 gene encodes the AMPK α2 subunit.

Purpose of the Study:

• To investigate the role of AMPK α2 in cutaneous melanoma development and progression.
• To determine the relationship between AMPKα2 mutations and NF1 mutations in melanoma.
• To evaluate the therapeutic potential of targeting AMPK in melanoma brain metastasis.

Main Methods:

• Analysis of the TCGA melanoma dataset for PRKAA2 mutations.
• In vitro soft agar assays to assess anchorage-independent growth (knockout vs. ectopic expression of AMPKα2).
• In vivo studies in immune-deficient mice to evaluate tumor growth and brain metastasis.

Main Results:

• Approximately 9% of cutaneous melanomas harbor mutations in the PRKAA2 gene, often co-occurring with NF1 mutations.
• AMPKα2 knockout promoted, while its ectopic expression inhibited, anchorage-independent growth of NF1-mutant melanoma cells.
• Loss of AMPKα2 accelerated tumor growth and enhanced brain metastasis in NF1-mutant melanoma models.

Conclusions:

• AMPKα2 functions as a tumor suppressor in NF1-mutant melanoma.
• Loss of AMPKα2 contributes to melanoma progression and brain metastasis.
• AMPK represents a potential therapeutic target for treating melanoma brain metastasis.